Company Description
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.
The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.
In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.
| Country | United States |
| Founded | 2020 |
| IPO Date | Aug 3, 2023 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Erez Aminov |
Contact Details
Address: 1200 Brickell Avenue, Suite 1950 #1183 Miami, Florida 32183 United States | |
| Phone | 786 432 9792 |
| Website | mirapharmaceuticals.com |
Stock Details
| Ticker Symbol | MIRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $7.00 |
| CIK Code | 0001904286 |
| CUSIP Number | 60458C104 |
| ISIN Number | US60458C1045 |
| Employer ID | 85-3354547 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Erez Aminov | Chief Executive Officer and Chairman |
| Michelle Yanez M.B.A. | Chief Financial Officer, Secretary and Treasurer |
| Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | 10-K | Annual Report |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 8-K | Current Report |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 19, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 8-K | Current Report |
| Nov 21, 2024 | 8-K | Current Report |
| Nov 19, 2024 | 144 | Filing |
| Nov 19, 2024 | 8-K | Current Report |